Connect public, paid and private patent data with Google Patents Public Datasets

Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same

Download PDF

Info

Publication number
USRE36939E
USRE36939E US08652690 US65269096A USRE36939E US RE36939 E USRE36939 E US RE36939E US 08652690 US08652690 US 08652690 US 65269096 A US65269096 A US 65269096A US RE36939 E USRE36939 E US RE36939E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
liquid
medicament
ultrasound
microbubbles
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08652690
Inventor
Katsuro Tachibana
Shunro Tachibana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ekos Corp
Original Assignee
Ekos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0028Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0004Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0047Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin

Abstract

A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4×107 cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.

Description

This invention relates to a booster useful for enhancing the effects of ultrasound in the therapy of various diseases and a pharmaceutical liquid composition containing the booster and a medicament which shows enhanced diffusion and penetration of the medicament into the body by applying ultrasound. More particularly, it relates to a booster useful for therapy of various disease by applying ultrasound which comprises a plenty of microbubbles of a gas in a liquid, a pharmaceutical liquid composition comprising a plenty of microbubbles of a gas and a medicament in a liquid, and the use thereof in the therapy of various diseases while applying ultrasound.

Prior Art

It is known that various diseases are remedied by the aid of ultrasonic vibration. For example, it is described in Japanese Patent First Publication (Kokai) No. 115591/1977, etc. that percutaneous absorption of a medicament is enhanced by applying a ultrasonic vibration. Japanese Patent First Publication (Kokai) No. 180275/1990 discloses a drug-injecting device which is effective on the diffusion and penetration of the drug by applying a ultrasonic vibration in the step of injecting a drug into a human body via a catheter or a drug-injecting tube. U.S. Pat. Nos. 4,953,565 and 5,007,438 also disclose the technique of percutaneous absorption of medicaments by the aid of ultrasonic vibration. It is also reported that a tumor can be remedied by concentratedly applying ultrasound from outside the body.

In order to enhance the therapeutic effects with ultrasound, it is required to apply a higher energy of a ultrasonic vibration. However, too higher energy of a ultrasonic vibration causes disadvantageously burns or unnecessary heat at the portion other than the desired portion. On the other hand, when the energy of a ultrasonic vibration is lowered for eliminating such disadvantages, there is a problem of less effect of the ultrasound at the desired portion.

SUMMARY DESCRIPTION OF THE INVENTION

The present inventors have intensively studied on the enhancement of the effects of ultrasound with a lower energy of a ultrasonic vibration and have found that a booster comprising a plenty of microbubbles of a gas in a liquid is useful for the desired enhancement of the effects of ultrasound.

An object of the invention is to provide a booster useful for enhancing the effects of ultrasound which comprises a plenty of microbubbles of a gas in a liquid. Another object of the invention is to provide a pharmaceutical liquid composition containing the booster and a medicament which is useful for the therapy of various diseases together with the application of ultrasound. A further object of the invention is to provide a method for enhancing the effects by the application of ultrasound in the therapy of various diseases which comprises injecting the booster or the pharmaceutical liquid composition as set forth above into the portion to be remedied while applying ultrasound thereto. These and other objects and advantages of the invention will be apparent to those skilled in the art from the following description.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows a schematic view of one of the micro-bubbles contained in the booster of the invention.

FIG. 2 shows a schematic sectional view of one embodiment of a drug administration device used for injecting, pouring, applying or circulating the booster or the pharmaceutical liquid composition of the invention.

FIG. 3 shows a schematic sectional view of one embodiment of a drug administration device used for percutaneous injection of the booster or the pharmaceutical liquid composition of the invention.

FIG. 4 and FIG. 5 show graphs showing fibrinolysis by application of ultrasound with or without the booster of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The booster of the invention comprises a liquid containing a plenty of microbubbles of a gas having a diameter of 0.1 to 100 μm. The microbubbles are formed by entrapping microspheres of a gas into a liquid. The booster contains, for example, about 4×107 of the microbubbles per one milliliter of a liquid. The microbubbles are made of various gases such as air, oxygen gas, carbon dioxide gas, inert gases (e.g. xenon, krypton, argon, neon, helium, etc.), preferably air and oxygen gas. The liquid includes any liquid which can form microbubbles, for example, human serum albumin (e.g. 3 to 5% human serum albumin), a physiological saline solution, a 5% aqueous glucose solution, an aqueous indocyanine green solution, autoblood, an aqueous solution of maglumine diatriazoate (=renografin), and any other X-ray contrast medium.

The booster can be prepared by a known method, for example, by agitating the liquid as mentioned above while blowing a gas as mentioned above into the liquid, or alternatively exposing the liquid to ultrasound with a sonicator under a gaseous atmosphere, whereby a vibration is given to the liquid to form microbubbles of the gas.

The pharmaceutical liquid composition of the invention comprises a plenty of microbubbles of a gas and a medicament in a liquid. The microbubbles of a gas and liquid are the same as mentioned above. The medicament includes any known medicaments effective for the desired therapy which can be absorbed percutaneously, for example, anti-thrombosis agents (e.g. urakinase, tissue plasminogen activator, etc.), hormones (e.g. insulin, etc.), theophylline, lidocaine, antibiotics, antineoplastic agents which are sensitive to ultrasound (e.g. doxorubicin (=adriamycin), cytarabine (=Ara-C), etc.), and the like. The medicament can be contained in a therapeutically effective amount as usually used. The pharmaceutical liquid composition can be prepared by mixing a medicament with a booster comprising a plenty of microbubbles of a gas in a liquid. The mixing ratio may vary depending on the desired amount and kind of the medicament and the kind of the liquid, but is usually in a range of 1:100 to 100:1 by weight (a medicament/a booster).

According to the invention, the therapeutic effects by ultrasound is boosted by the presence of a booster of the invention. Particularly, when a pharmaceutical liquid composition containing the booster and a medicament is poured or injected into a body in parenteral routes, such as intravenously, percutaneously or intramuscularly, while applying thereto a ultrasonic vibration, the therapeutic effects of the medicament is significantly enhanced. When a ultrasound from a ultrasonic element is applied to the liquid containing the booster and medicament, cavitation occurs in the liquid composition, and the medicament is diffused and penetrated into the desired portion of the biobody by the aid of vibration induced by the cavitation. The cavitation occurs when the level of vibration energy overs a certain threshold value. When the ultrasound is applied to the liquid composition of the invention, the threshold value of the vibration energy lowers due to the presence of a plenty of microbubbles of a gas. That is, the microbubbles of a gas act as nucleus of cavitation and thereby the cavitation occurs more easily. Accordingly, according to the invention, the desired ultrasonic energy necessary for the desired diffusion and penetration of a medicament is achieved even by less energy of ultrasonic vibration energy.

The desired ultrasound is applied by conventional ultrasonic devices which can supply a ultrasonic signal of 20 KHz to several MHz.

With reference to the accompanying drawing, the invention is illustrated in more detail.

FIG. 1 shows a schematic view of one of the plenty of microbubbles of a gas contained in the booster of the invention, wherein the microbubble of a gas has a diameter of 0.1 to 100 μm and is composed of a shell of human serum albumin (1) and gas (2) entrapped within the microbubble. The microbubbles are contained in a liquid (3) such as 5% human serum albumin solution in an amount of, for example, above 4×107 cells/ml.

The booster is mixed with a medicament to give a pharmaceutical liquid composition. The pharmaceutical liquid composition is directly administered to the diseased part with an appropriate device, for example, with a drug administration device (4) as shown in FIG. 2. The drug administration device (4) comprises a base tube (5) to which the pharmaceutical liquid composition is supplied, and an end tube (6) which is to be inserted into the tissue of the biobody and through which the pharmaceutical liquid composition is poured or injected into the diseased part. The end tube (6) is provided with a ultrasonic element (7) (e.g. a cylindrical ceramic oscillator, etc.). The ultrasonic element (7) is supplied by a ultrasonic signal of 20 kHz to several MHz from a ultrasonic oscillation circuit (8) via a conductor (9a), connectors (10a) and (10b) provided on the side of the base tube (5), a part of the base tube (5) and a conductor (9b) provided within the end tube (6).

The application or injection of a medicament is carried out in the form of a pharmaceutical liquid composition which is prepared by previously mixing the medicament with the booster comprising a plenty of microbubbles of a gas in a liquid, wherein the medicament and the booster are mixed in a ratio of 1:100 to 100:1 by weight. The pharmaceutical liquid composition is poured into the base tube (5) from the supply opening (11) provided on the tip of the base tube (5), passes through a flow path (12) within the base tube (5) and a flow path (13) within the end tube (6) and then administered to the diseased part or the portion close thereto of the patient via a pouring opening (14) provided at the bottom of the end tube (6).

When the pharmaceutical liquid composition is administered into the diseased part or the portion close thereto through the pouring opening (14), a ultrasonic energy generated from a ultrasonic element (7) is given to the liquid composition, by which cavitation occurs owing to the ultrasonic energy. Microbubbles are formed at the occurrence of cavitation and when the microbubbles are decomposed, energy is generated, by which diffusion and penetration of the medicament is promoted. Since the pharmaceutical liquid composition contains a plenty of microbubbles of a gas, the microbubbles act as a nucleus for the cavitation, by which the cavitation occurs more easily, in other words, the threshold value of occurrence of cavitation lowers. Accordingly, it is possible to generate the cavitation with less energy than the case of using no booster.

When a ultrasonic vibration is applied to a liquid, if the liquid contains any material being able to become a nucleus, the cavitation occurs generally at a lower threshold value of energy, but it has been found that the cavitation occurs most easily where the liquid contains microbubbles of a gas having a diameter of 0.1 to 100 μm.

The drug administration device (4) as shown in FIG. 2 can be used, for example, for administering a pharmaceutical liquid composition into a blood vessel. For instance, in the treatment of coronary thrombosis, a pharmaceutical liquid composition comprising a booster of the invention and a urokinase is injected into the part of thrombosis or the close portion thereof with the drug administration device (4) where the tip of the end tube (6) is inserted into the portion close to the thrombosis with applying ultrasound, by which the thrombolytic effects of the medicament are significantly increased and further the blood flow is recovered within a shorter period of time in comparison with the administration of the medicament without the booster. The drug administation device (4) may also be used for the removing hematoma in bleeding of brain. For example, a pharmaceutical liquid composition comprising a booster of the invention and a thromolytic agent (e.g. urokinase) is administered to the portion of hematoma with the drug administration device (4) with applying ultrasound like the above, by which the hematoma is easily lysed.

In another embodiment of the invention, the pharmaceutical liquid composition can be administered percutaneously with a drug administration device (15) as shown in FIG. 3.

In the drug administration device (15) suitable for percutaneous administration of a medicament, a layer of a medicament (17) is provided below a ultrasonic element (16) (e.g. a disc shaped ceramic oscillator, etc.), under of which an adhesive layer (18) having a medicament permeability is laminated, whole of which is covered with a plastic cover (19). The ultrasonic element (16) is supplied by ultrasonic signal from a ultrasonic oscillation circuit provided outside via a connector (20) like in the drug administration device (4) as shown in FIG. 2.

In the device (15) of FIG. 3, a pharmaceutical liquid composition comprising a mixture of a booster and a medicament is contained in the layer of a medicament (17). When this device (15) is used, it is adhered onto the skin with facing the adhesive layer (18) to the skin, and then a ultrasonic signal is supplied to the ultrasonic element (16), by which a ultrasonic vibration from the ultrasonic element (16) is given to both of the medicament layer (17) and the skin and thereby the medicament contained in the medicament layer (17) is passed through the skin and is penetrated into the tissue to be treated. In this embodiment, since microbubbles of a gas are contained in the medicament layer (17), cavitation occurs easily within the medicament layer (17) by application of ultrasound, and hence even lower energy of the ultrasonic vibration is supplied from the ultrasonic element (16), the diffusion and penetration of the medicament can effectively be done to result in rapid absorption of the medicament.

The booster of the invention may also be used alone without mixing with a medicament in the therapy with ultrasound. For example, in the therapy of tumors by heating the diseased part of the tissue with ultrasound, that is, by concentratedly applying a ultrasonic vibration outside the biobody, a booster comprising a plenty of microbubbles of a gas in a liquid of the invention is previously injected into the blood vessel or to the portion close to the diseased part before application of ultrasound, by which the effect of heating with ultrasound is enhanced and thereby the therapeutic effects are significantly improved. In this embodiment, cavitation occurs also by the ultrasonic vibration more easily because of using a liquid containing microbubbles of a gas, and hence, even by less energy of the ultrasonic vibration suppled from the ultrasonic element, the ultrasonic energy sufficient to the therapy is obtained and thereby the undesirable burns and unnecessary heating at other portions can be avoided.

In the treatment of tumors, it is, of course, more effective to use it together with a chemotherapeutic agent suitable for the treatment of the tumors, by which the effects of the chemotherapeutic agent are more enhanced, where the diffusion and penetration of the medicament are improved owing to the booster.

The substance such as human serum albumin in the booster of the invention is easily metabolized within the biobody and excreted outside the biobody, and hence, it is not harmful to human body. Besides, the gas trapped within the microbubbles is extremely small and is easily dissolved in the blood fluid. Accordingly, the booster of the invention has no problem in the safety thereof.

The preparation of the booster and pharmaceutical liquid composition of the invention and effects thereof are illustrated by the following Examples and Experiment, but it should not be construed to be limited thereto.

EXAMPLE 1

Preparation of a Booster:

A 5% human serum albumin (8 ml) in a 10 ml-volume syringe is exposed to ultrasound with a sonicator (frequency, 20 KHz) by which vibration is given to the human serum albumin and a plenty of microbubbles of air are formed in the human serum albumin to give a booster comprising a human serum albumin containing a plenty of microbubbles of air.

EXAMPLE 2

Preparation of a Pharmaceutical Liquid Composition:

The 5% human serum albumin containing a plenty of microbubbles of air prepared in Example 1 is mixed with urokinase (concentration 1200 IU/ml) to give the desired pharmaceutical liquid composition.

Experiment 1. Forming Artificial Thrombosis

An artificial thrombosis was formed by Chandler's method. A blood (1 ml) collected from healthy human (two persons) was entered into a flexibale tube (inside diameter 3 mm, length 265 mm) and thereto was added calcium chloride, and then the tube was made a loop like shape, which was rotated at 12 r.p.m. for 20 minutes to give an artificial thrombosis model.

2. Ultrasonic Catheter

A ceramic ultrasonic element (width 2 mm, length 5 mm, thickness 1 mm) was inserted into the tip of a cetheter (diameter 2 mm), and an oscillating element was connected to an oscillator provided outside with a fine connector passed through the catheter. A fine tube for pouring a test solution was provided at an opening opposite to the opening of the catheter end.

3. Test Method

The artificial thrombosis prepared above was added to a test tube together with a blood, and the ultrasonic catheter was inserted into the test tube so that the end of the catheter was set close to the portion of the artificial thrombosis (at a distance of about 5 mm), and to the test tube a mixture of urokinase and a booster prepared in Example 1 was added at a rate of 1 ml per minute, wherein urokinase (concentration 1200 IU/ml) and the booster were mixed immediately before pouring at a mixing ratio of 1:1 by weight. The mixture was refluxed while keeping the volume of the test solution at a constant level by removing excess volume of the solution by suction. The ultrasound (170 KHz) was exposed to the mixture by a pulse method (exposed for 2 seconds and stopped for 4 seconds) for 2 minutes (total exposing time 40 seconds). After the exposure, the ultrasonic catheter was removed from the test tube, and the mixture was incubated at 37° C. for 5 to 120 minutes, washed with a physiological saline solution several times and dried overnight. Thereafter, the dried mixture was weighed. As a control, the above was repeated by using only a physiological saline solution.

4. Test Results

The rate of fibrinolysis was calculated by the following equation: ##EQU1##

The results are shown in the accompanying FIGS. 4 and 5 wherein there are shown in average of twice tests.

FIG. 4 shows the results in the thrombosis prepared by using blood collected from one person, wherein the symbol -- is the data obtained in the addition of urokinase alone without exposure of ultrasound, - ♦- is the data obtained in the addition of urokinase alone with exposure of ultrasound, and -▪- is the data obtained in the addition of a mixture of urokinase and the booster with exposure of ultrasound.

As is shown in FIG. 4, the time for achieving 20% fibrinolysis was 45 minutes by urokinase alone without exposure of ultrasound, 30 minutes by a combination of urokinase and exposure of ultrasound, and only 10 minutes by a combination of a mixture of urokinase and a booster and exposure of ultrasound. The fibrinolytic effects of urokinase (both the rate of fibrinolysis and the fibrinlytic time) were signigicantly enhanced by using a booster with application of ultrasound.

FIG. 5 shows the results in the thrombosis prepared by using blood collected from another person and with reduced energy of ultrasound by 15%, wherein the symbols are the same as in FIG. 4. As is shown in FIG. 5, the fibrinolytic effects were significantly enhanced by using a mixture of urokinase and the booster. That is, in case of using urokinase alone with exposure of ultrasound, the 50% fibrinolysis was achieved by the treatment for 60 minutes, but in case of using a mixture of urokinase and the booster with exposure of ultrasound, it reduced to one fourth, i.e. it was achieved by the treatment only for 15 minutes.

Claims (18)

What is claim is:
1. A .[.booster.]. .Iadd.composition .Iaddend.for enhancing effects of ultrasound in the therapy of diseases, which comprises:
.Iadd.a liquid; .Iaddend.
.[.a..]. a medicament.Iadd.; .Iaddend.and
.[.b..]. microbubbles of a gas having a diameter of 0.1 to 100 μm.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles.Iaddend..
2. The .[.booster.]. .Iadd.composition .Iaddend.according to claim 1, wherein the microbubbles are formed from air or oxygen gas in the liquid.
3. The .[.booster.]. .Iadd.composition .Iaddend.according to claim 1, wherein the liquid is a 3 to 5% human serum albumin solution.
4. A pharmaceutical liquid composition for the therapy of diseases with application of ultrasound, which comprises:
.Iadd.a liquid; .Iaddend.
.[.a..]. microbubbles of a gas having a diameter of 0.1 to 100 μm.Iadd.; .Iaddend.and
.[.b..]. a medicament selected from the group consisting of thrombolytic agents, hormones, antibiotics and antineoplastic agents.Iadd., .Iaddend..[.in a liquid.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles.Iaddend..
5. The composition according to claim 4, wherein the microbubbles are formed from air or oxygen gas in the liquid.
6. The composition according to claim 4, wherein the liquid is a 3 to 5% human serum albumin solution. .[.7. The composition according to claim 4, wherein the medicament is a member selected from thromobolytic agents,
hormones, antibiotics, and antineoplastic agents..].8. The composition according to claim 4, wherein the medicament is selected from the group consisting of urokinase, tissue plasminogen activator, insulin,
theophylline, and lidocaine. 9. A method for enhancing the therapeutic effects of a medicament, comprising:
.[.a. applying ultrasound to a pharmaceutical liquid composition according to claim 4 and
b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical liquid composition .Iadd.comprising a liquid, a medicament, and microbubbles of a gas having a diameter of 0.1 to 100 μm, wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the pharmaceutical liquid composition.Iaddend.. 10. The method according to claim 9, wherein the liquid composition comprises about 4×107 cells/ml of microbubbles .[.of a gas having a diameter of 0.1 to 100 μm and a medicament in the liquid.]..
. The method according to claim 10, wherein the liquid is a 3 to 5%
human serum albumin solution. 12. The method according to claim 9, wherein the medicament is selected from the group consisting of urokinase, tissue
plasminogen activator, insulin, theophylline, and lidocaine. 13. A method of dosing subjects with a pharmaceutical preparation by:
.[.a. applying ultrasound to a pharmaceutical liquid composition and.].
.[.b..]. administering .[.said.]. .Iadd.a .Iaddend.pharmaceutical liquid composition comprising .Iadd.a liquid, .Iaddend.microbubbles of a gas having a diameter of 0.1 to 100 μm.Iadd., .Iaddend.and a medicament .[.in a liquid in the therapy of diseases.]. .Iadd.wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the pharmaceutical liquid composition.Iaddend.. 14. The method of dosing according to claim 13, wherein the microbubbles
are formed from air or oxygen gas in the liquid. 15. The method of dosing according to claim 13, wherein the liquid is a 3 to 5% human serum albumin
solution. 16. The method of dosing according to claim 13, wherein the medicament is selected from the group consisting of urokinase, tissue
plasminogen activator, insulin, theophylline, and lidocaine. .Iadd.17. A composition for enhancing the effects of ultrasound in the therapy of diseases when said ultrasound is administered in conjunction with a medicament, said composition comprising a liquid, a medicament, and microbubbles of a gas made of a shell having a diameter of 0.1 to 100 μm, wherein a majority of the medicament is present outside of the shell and is not incorporated in the shell. .Iaddend..Iadd.18. A composition for enhancing the effects of ultrasound in the therapy of diseases which comprises a liquid, a medicament, and microbubbles of a gas made of a shell having a diameter of 0.1 to 100 μm, wherein at least a majority of the medicament is present outside of the shell.
.Iaddend..Iadd.9. A method for enhancing the therapeutic effects of ultrasound comprising:
creating a mixture comprising a liquid, microbubbles of a gas having a diameter of 0.1 to 100 μm, and a medicament, wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the mixture. .Iaddend..Iadd.20. The method of claim 19 wherein the mixture is administered in proximity to a diseased part. .Iaddend..Iadd.21. The method of claim 19 wherein the mixture is injected into a blood vessel near a diseased part. .Iaddend..Iadd.22. A method for enhancing the therapeutic effect of a medicament administered to a patient comprising:
administering to the patient a liquid composition comprising microbubbles of a gas having a diameter of 0.1 to 100 μm; and
applying ultrasound to the liquid composition and the medicament, wherein a majority of the medicament is present outside of the microbubbles. .Iaddend..Iadd.23. The method of claim 22 wherein the mixture is injected into a blood vessel near a diseased part. .Iaddend..Iadd.24. A method of enhancing the therapeutic effects of ultrasound of a medicament comprising:
creating microbubbles of a gas having a diameter of 0.1 to 100 μm in a liquid containing the medicament, wherein a majority of the medicament is present outside of the microbubbles; and
applying ultrasound to the microbubbles. .Iaddend..Iadd.25. The method of claim 24 wherein the liquid is administered in the proximity of a diseased part. .Iaddend..Iadd.26. The method of claim 24 wherein the liquid is injected in a blood vessel near the diseased part. .Iaddend.
US08652690 1991-03-22 1996-05-30 Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same Expired - Lifetime USRE36939E (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP5897091 1991-03-22
JP3-058970 1991-03-22
US07855545 US5315998A (en) 1991-03-22 1992-03-20 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US08652690 USRE36939E (en) 1991-03-22 1996-05-30 Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08652690 USRE36939E (en) 1991-03-22 1996-05-30 Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same
US09375339 US6585678B1 (en) 1991-03-22 1999-08-16 Booster for therapy of disease with ultrasound and pharmaceutical IDLIQU composition containing the same
US10400337 US20030191446A1 (en) 1991-03-22 2003-03-26 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US12172686 US20080274097A1 (en) 1991-03-22 2008-07-14 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US07855545 Reissue US5315998A (en) 1991-03-22 1992-03-20 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US07855545 Division US5315998A (en) 1991-03-22 1992-03-20 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09375339 Division US6585678B1 (en) 1991-03-22 1999-08-16 Booster for therapy of disease with ultrasound and pharmaceutical IDLIQU composition containing the same

Publications (1)

Publication Number Publication Date
USRE36939E true USRE36939E (en) 2000-10-31

Family

ID=13099707

Family Applications (5)

Application Number Title Priority Date Filing Date
US07855545 Expired - Lifetime US5315998A (en) 1991-03-22 1992-03-20 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US08652690 Expired - Lifetime USRE36939E (en) 1991-03-22 1996-05-30 Composition for therapy of diseases with ultrasonic and pharmaceutical liquid composition containing the same
US09375339 Expired - Fee Related US6585678B1 (en) 1991-03-22 1999-08-16 Booster for therapy of disease with ultrasound and pharmaceutical IDLIQU composition containing the same
US10400337 Abandoned US20030191446A1 (en) 1991-03-22 2003-03-26 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US12172686 Abandoned US20080274097A1 (en) 1991-03-22 2008-07-14 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07855545 Expired - Lifetime US5315998A (en) 1991-03-22 1992-03-20 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same

Family Applications After (3)

Application Number Title Priority Date Filing Date
US09375339 Expired - Fee Related US6585678B1 (en) 1991-03-22 1999-08-16 Booster for therapy of disease with ultrasound and pharmaceutical IDLIQU composition containing the same
US10400337 Abandoned US20030191446A1 (en) 1991-03-22 2003-03-26 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US12172686 Abandoned US20080274097A1 (en) 1991-03-22 2008-07-14 Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same

Country Status (4)

Country Link
US (5) US5315998A (en)
CA (1) CA2063529A1 (en)
DE (2) DE69215722D1 (en)
EP (2) EP0504881B2 (en)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066060A2 (en) * 2001-02-19 2002-08-29 Dornier Medtech Systems Gmbh Method and device for ultrasound-assisted transmembrane medicament application in vitro
US6478754B1 (en) * 2001-04-23 2002-11-12 Advanced Medical Applications, Inc. Ultrasonic method and device for wound treatment
US6514221B2 (en) * 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US6533803B2 (en) 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US6569099B1 (en) 2001-01-12 2003-05-27 Eilaz Babaev Ultrasonic method and device for wound treatment
WO2003051208A1 (en) 2001-12-14 2003-06-26 Ekos Corporation Blood flow reestablishment determination
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
US6623444B2 (en) 2001-03-21 2003-09-23 Advanced Medical Applications, Inc. Ultrasonic catheter drug delivery method and device
US20040002677A1 (en) * 2001-12-11 2004-01-01 Gentsler Curtis C. Alternate site gene therapy
US6761729B2 (en) 2000-12-22 2004-07-13 Advanced Medicalapplications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US20040248832A1 (en) * 2001-07-10 2004-12-09 Michael Davidson Enhancement of transfection of dna into the liver
US20060058708A1 (en) * 2003-12-24 2006-03-16 Gill Heart Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue
WO2006063199A2 (en) 2004-12-09 2006-06-15 The Foundry, Inc. Aortic valve repair
US20060144801A1 (en) * 2003-07-08 2006-07-06 Mario Swinnen Device and process for treating cutting fluids using ultrasound
US20070016041A1 (en) * 2005-06-24 2007-01-18 Henry Nita Methods and apparatus for intracranial ultrasound delivery
US20070055179A1 (en) * 2005-09-07 2007-03-08 Deem Mark E Method for treating subcutaneous tissues
US20070158273A1 (en) * 1996-07-04 2007-07-12 Eric Cordemans De Meulenaer Device and process for treating a liquid medium
US20070183976A1 (en) * 2006-01-06 2007-08-09 Imarx Therapeutics, Inc. Composition for ultrasound therapy and pharmaceutical liquid composition containing the same
US20070265560A1 (en) * 2006-04-24 2007-11-15 Ekos Corporation Ultrasound Therapy System
US20080004649A1 (en) * 2006-06-07 2008-01-03 Bacoustics Llc Apparatus and methods for debridement with ultrasound energy
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080056937A1 (en) * 2002-11-04 2008-03-06 Ashland Licensing And Intellectual Property Llc Device and Process for Treating a Liquid Medium Using Ultrasound
US20080089912A1 (en) * 2006-10-11 2008-04-17 Dimauro Thomas Intrathecal Injection of Microbubbles Containing a Thrombolytic Agent
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080248554A1 (en) * 2005-12-02 2008-10-09 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080274097A1 (en) * 1991-03-22 2008-11-06 Katsuro Tachibana Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US7448859B2 (en) 2004-11-17 2008-11-11 Ashland Licensing And Intellectual Property Llc Devices and method for treating cooling fluids utilized in tire manufacturing
US20100081934A1 (en) * 2004-01-30 2010-04-01 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
US7713218B2 (en) 2005-06-23 2010-05-11 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US7785277B2 (en) 2005-06-23 2010-08-31 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US7878991B2 (en) 2006-08-25 2011-02-01 Bacoustics, Llc Portable ultrasound device for the treatment of wounds
US7914470B2 (en) 2001-01-12 2011-03-29 Celleration, Inc. Ultrasonic method and device for wound treatment
US20110160621A1 (en) * 2005-06-24 2011-06-30 Henry Nita Methods and apparatus for dissolving intracranial blood clots
US8235919B2 (en) 2001-01-12 2012-08-07 Celleration, Inc. Ultrasonic method and device for wound treatment
US8491521B2 (en) 2007-01-04 2013-07-23 Celleration, Inc. Removable multi-channel applicator nozzle
US8562547B2 (en) 2006-06-07 2013-10-22 Eliaz Babaev Method for debriding wounds
EP2727544A1 (en) 2012-11-05 2014-05-07 Ekos Corporation Catheter systems and methods
US8740835B2 (en) 2010-02-17 2014-06-03 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
US8894678B2 (en) 2009-08-07 2014-11-25 Ulthera, Inc. Cellulite treatment methods
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9039722B2 (en) 2007-10-09 2015-05-26 Ulthera, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
US9102553B2 (en) 2004-06-23 2015-08-11 Solenis Technologies, L.P. Devices and methods for treating fluids utilized in electrocoating processes with ultrasound
US9272124B2 (en) 2005-12-02 2016-03-01 Ulthera, Inc. Systems and devices for selective cell lysis and methods of using same
US9295552B2 (en) 2011-10-19 2016-03-29 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9375223B2 (en) 2009-10-06 2016-06-28 Cardioprolific Inc. Methods and devices for endovascular therapy
US9421098B2 (en) 2010-12-23 2016-08-23 Twelve, Inc. System for mitral valve repair and replacement
US9572662B2 (en) 2011-06-21 2017-02-21 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
US9763780B2 (en) 2011-10-19 2017-09-19 Twelve, Inc. Devices, systems and methods for heart valve replacement

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5713848A (en) * 1993-05-19 1998-02-03 Dubrul; Will R. Vibrating catheter
US5701899A (en) * 1993-05-12 1997-12-30 The Board Of Regents Of The University Of Nebraska Perfluorobutane ultrasound contrast agent and methods for its manufacture and use
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
EP1550464A1 (en) * 1993-07-30 2005-07-06 IMCOR Pharmaceutical Co. Stabilized microbubble composition for ultrasound
DK0717617T3 (en) 1993-09-09 2001-02-05 Schering Ag Microparticles containing active ingredients and gas
DE4330958A1 (en) * 1993-09-09 1995-03-16 Schering Ag Novel microparticles containing active compound, media containing these, their use for the ultrasonically controlled release of active compounds and process for the production thereof
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
WO1996022111A1 (en) * 1995-01-19 1996-07-25 Sound Science Limited Partnership Local delivery and monitoring of drugs
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5804162A (en) * 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5648098A (en) * 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
US5725494A (en) 1995-11-30 1998-03-10 Pharmasonics, Inc. Apparatus and methods for ultrasonically enhanced intraluminal therapy
US6221038B1 (en) 1996-11-27 2001-04-24 Pharmasonics, Inc. Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers
US5735811A (en) 1995-11-30 1998-04-07 Pharmasonics, Inc. Apparatus and methods for ultrasonically enhanced fluid delivery
US5728062A (en) * 1995-11-30 1998-03-17 Pharmasonics, Inc. Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
DE69733815T2 (en) * 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Probe for excavation
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
DE69724599D1 (en) * 1996-03-12 2003-10-09 Univ Nebraska Lincoln Board Of Composition for destination-specific administration of a drug and methods of using
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US6234990B1 (en) 1996-06-28 2001-05-22 Sontra Medical, Inc. Ultrasound enhancement of transdermal transport
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846218A (en) 1996-09-05 1998-12-08 Pharmasonics, Inc. Balloon catheters having ultrasonically driven interface surfaces and methods for their use
US6464660B2 (en) 1996-09-05 2002-10-15 Pharmasonics, Inc. Balloon catheters having ultrasonically driven interface surfaces and methods for their use
WO1998010798A1 (en) 1996-09-11 1998-03-19 Imarx Pharmaceutical Corp. Improved methods for diagnostic imaging using a contrast agent and a vasodilator
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6024717A (en) * 1996-10-24 2000-02-15 Vibrx, Inc. Apparatus and method for sonically enhanced drug delivery
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6228046B1 (en) 1997-06-02 2001-05-08 Pharmasonics, Inc. Catheters comprising a plurality of oscillators and methods for their use
US5931805A (en) * 1997-06-02 1999-08-03 Pharmasonics, Inc. Catheters comprising bending transducers and methods for their use
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
WO1999033391A3 (en) 1997-12-31 1999-09-16 Pharmasonics Inc Methods and systems for the inhibition of vascular hyperplasia
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
US8287483B2 (en) * 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US7273458B2 (en) 1998-01-12 2007-09-25 Georgia Tech Research Corporation Method of applying acoustic energy effective to alter transport or cell viability
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JPH11244283A (en) * 1998-03-05 1999-09-14 Ge Yokogawa Medical Systems Ltd Ultrasonic image pickup method and its device
US6723063B1 (en) 1998-06-29 2004-04-20 Ekos Corporation Sheath for use with an ultrasound element
US6210356B1 (en) * 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US20040171980A1 (en) * 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US6361554B1 (en) 1999-06-30 2002-03-26 Pharmasonics, Inc. Methods and apparatus for the subcutaneous delivery of acoustic vibrations
US6387116B1 (en) 1999-06-30 2002-05-14 Pharmasonics, Inc. Methods and kits for the inhibition of hyperplasia in vascular fistulas and grafts
EP1202670A4 (en) * 1999-08-13 2004-11-10 Point Biomedical Corp Hollow microspheres with controlled fragility for medical use
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6944493B2 (en) * 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
US6439236B1 (en) 1999-10-25 2002-08-27 The Board Of Regents Of The University Of Nebraska Methods for inducing atrial and ventricular rhythms using ultrasound and microbubbles
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US20040158317A1 (en) * 2000-07-18 2004-08-12 Pharmasonics, Inc. Coated stent with ultrasound therapy
CN100586497C (en) 2000-09-25 2010-02-03 阿得旺思特医药申请有限公司 Ultrasonic device for wound treatment
US6964647B1 (en) * 2000-10-06 2005-11-15 Ellaz Babaev Nozzle for ultrasound wound treatment
DE60237201D1 (en) * 2001-01-26 2010-09-16 Yoni Iger Apparatus for relief of substances of biological components
US6960173B2 (en) * 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
DE10119522A1 (en) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Production and application of a suspension composition with an ultrasound contrast agent
US8123789B2 (en) * 2002-04-29 2012-02-28 Rohit Khanna Central nervous system cooling catheter
EP1647232B1 (en) 2001-12-03 2011-08-17 Ekos Corporation Catheter with multiple ultrasound radiating members
US7699778B2 (en) 2002-02-21 2010-04-20 Technion Research & Development Foundation Ltd. Ultrasound cardiac stimulator
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
JP4243499B2 (en) * 2002-06-11 2009-03-25 富士通株式会社 Bonded substrate manufacturing apparatus and the bonded substrate manufacturing method pasting
WO2004016311A3 (en) * 2002-07-22 2004-05-06 Hans-Werner Bender Ultrasonic applicator device with a flat, flexible ultrasonic applicator and cavitation medium
US6921371B2 (en) * 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
JP2004182728A (en) * 2002-11-22 2004-07-02 Misako Nakajima Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue
CA2545798A1 (en) * 2003-02-19 2004-09-02 Dermisonics, Inc. Ultrasonically enhanced saline treatment for burn damaged skin
DK2351844T3 (en) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Compositions for enhancing the transport and antisense efficiency of nucleic acid into cells
WO2005056105A8 (en) * 2003-12-11 2006-09-28 Hans-Werner Bender Device consisting of a sonic applicator and a carrier element
EP1713537A4 (en) 2004-01-29 2009-04-29 Ekos Corp Method and apparatus for detecting vascular conditions with a catheter
US20060094945A1 (en) * 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
WO2006110773A3 (en) * 2005-04-12 2007-07-26 Ekos Corp Ultrasound catheter with cavitation promoting surface
US9101949B2 (en) * 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US20070031611A1 (en) * 2005-08-04 2007-02-08 Babaev Eilaz P Ultrasound medical stent coating method and device
US7896539B2 (en) * 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
US9486274B2 (en) * 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
WO2007030415A3 (en) * 2005-09-07 2007-09-20 The Foundry Inc Apparatus and method for disrupting subcutaneous structures
GB0518273D0 (en) * 2005-09-08 2005-10-19 Univ Dundee Apparatus and method for sonoporation
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
US20080097316A1 (en) * 2006-08-21 2008-04-24 Leonid Malinin Ultrasound catheter
US8257338B2 (en) * 2006-10-27 2012-09-04 Artenga, Inc. Medical microbubble generation
US8192363B2 (en) * 2006-10-27 2012-06-05 Ekos Corporation Catheter with multiple ultrasound radiating members
US20080142616A1 (en) * 2006-12-15 2008-06-19 Bacoustics Llc Method of Producing a Directed Spray
WO2008079379A1 (en) * 2006-12-22 2008-07-03 Celleration, Inc. Apparatus to prevent applicator re-use
WO2008085911A1 (en) * 2007-01-04 2008-07-17 Celleration, Inc. Removable multi-channel applicator nozzle
US20090018472A1 (en) * 2007-01-08 2009-01-15 Azita Soltani Power parameters for ultrasonic catheter
RU2444980C2 (en) * 2007-03-07 2012-03-20 Эко Терапьютикс, Инк. Transdermal system of analite monitoring and methods of analite detection
CN101707872B (en) 2007-04-27 2014-10-22 回声治疗有限公司 Skin penetration means for sensing an analyte, or transdermal administration
EP2170181B1 (en) 2007-06-22 2014-04-16 Ekos Corporation Method and apparatus for treatment of intracranial hemorrhages
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus
US20090093723A1 (en) * 2007-10-05 2009-04-09 Cabochon Aesthetics, Inc. Ultrasound device including dispenser
WO2009048969A1 (en) * 2007-10-09 2009-04-16 Cabochon Aesthetics, Inc. Ultrasound apparatus with treatment lens
US20090093738A1 (en) * 2007-10-09 2009-04-09 Cabochon Aesthetics, Inc. Device and method for monitoring a treatment area
CN100560157C (en) * 2007-11-13 2009-11-18 重庆市生力医疗设备有限公司 Ultrasonic medicine plaster
US8262645B2 (en) * 2007-11-21 2012-09-11 Actuated Medical, Inc. Devices for clearing blockages in in-situ artificial lumens
US20090187137A1 (en) * 2007-12-14 2009-07-23 Kim Volz Ultrasound pulse shaping
EP2231279A1 (en) * 2007-12-28 2010-09-29 Celleration, Inc. Methods for treating inflammatory skin disorders
DE102008038309A1 (en) * 2008-08-19 2010-02-25 Theuer, Axel E., Prof. Dr.-Ing. habil. A device for destruction of tumor cells or pathogens in the bloodstream
US20100106063A1 (en) * 2008-10-29 2010-04-29 Cabochon Aesthetics, Inc. Ultrasound Enhancing Target for Treating Subcutaneous Tissue
US8167280B2 (en) * 2009-03-23 2012-05-01 Cabochon Aesthetics, Inc. Bubble generator having disposable bubble cartridges
US20100256596A1 (en) * 2009-04-07 2010-10-07 Cabochon Aesthetics, Inc. Fiber growth promoting implants for reducing the appearance of cellulite
ES2503140T3 (en) 2009-07-03 2014-10-06 Ekos Corporation Power parameters for ultrasonic catheter
DE102010013703A1 (en) * 2010-04-01 2012-12-27 Oncowave Medical AG Apparatus for diagnosis and therapy of malignant tumor in patient, has ultrasound unit connected to control unit, which is switched to therapy mode to determine tumor-specific frequencies and lethal intensity during sonication of tumor
WO2013053099A1 (en) * 2011-10-10 2013-04-18 Liu Zheng Use of microbubble combined with ultrasonic cavitation in liver trauma hemostasis
US20160030725A1 (en) 2013-03-14 2016-02-04 Ekos Corporation Method and apparatus for treatment of intracranial hemorrhages

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961382A (en) * 1957-07-25 1960-11-22 Ortho Pharma Corp Urokinase-a plasmiogen activator and methods of obtaining the same
JPS52115591A (en) * 1976-02-09 1977-09-28 Fahim Mostafa S Method of local medication
WO1980002365A1 (en) * 1979-05-04 1980-11-13 Rasor Ass Inc Ultrasonic image enhancement
US4466442A (en) * 1981-10-16 1984-08-21 Schering Aktiengesellschaft Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
EP0224934A2 (en) * 1985-12-05 1987-06-10 Steven B. Feinstein Contrast agent, process for its preparation and its use for ultrasonic imaging
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
EP0278074A2 (en) * 1986-11-26 1988-08-17 Shunro Tachibana Apparatus for the endermic application of medicines
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
WO1989005160A1 (en) * 1987-12-02 1989-06-15 Schering Aktiengesellschaft Berlin Und Bergkamen Use of media containing bubbles in shock wave and ultrasonic therapy
WO1989005159A1 (en) * 1987-12-02 1989-06-15 Schering Aktiengesellschaft Berlin Und Bergkamen Ultrasonic or shock wave operating process and agent for implementing said process
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
EP0327490A1 (en) * 1988-02-05 1989-08-09 Schering Aktiengesellschaft Ultrasonic imaging agents, process for their preparation and their diagnostic and therapeutical use
US4900540A (en) * 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
WO1990001971A1 (en) * 1988-08-18 1990-03-08 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4936281A (en) * 1989-04-13 1990-06-26 Everest Medical Corporation Ultrasonically enhanced RF ablation catheter
JPH02180275A (en) * 1988-12-29 1990-07-13 Toshiro Tachibana Medicine injection tool having ultrasonic wave oscillation element
US5040537A (en) * 1987-11-24 1991-08-20 Hitachi, Ltd. Method and apparatus for the measurement and medical treatment using an ultrasonic wave
US5069664A (en) * 1990-01-25 1991-12-03 Inter Therapy, Inc. Intravascular ultrasonic angioplasty probe
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US558512A (en) * 1896-04-21 Strainer for coffee-pots
FR2445755B1 (en) 1979-01-08 1982-06-18 Harmand Pierre
US4657543A (en) * 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4750902A (en) * 1985-08-28 1988-06-14 Sonomed Technology, Inc. Endoscopic ultrasonic aspirators
DE3769676D1 (en) * 1986-03-14 1991-06-06 Fujisawa Pharmaceutical Co Prodrug compounds, processes for their preparation and sustained release formulations containing them.
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US4921478A (en) * 1988-02-23 1990-05-01 C. R. Bard, Inc. Cerebral balloon angioplasty system
US5158071A (en) 1988-07-01 1992-10-27 Hitachi, Ltd. Ultrasonic apparatus for therapeutical use
US4920954A (en) * 1988-08-05 1990-05-01 Sonic Needle Corporation Ultrasonic device for applying cavitation forces
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
ES2077595T3 (en) * 1990-03-16 1995-12-01 Siemens Ag Head of ultrasonic testing and procedure for operation.
US5197946A (en) 1990-06-27 1993-03-30 Shunro Tachibana Injection instrument with ultrasonic oscillating element
CA2022019C (en) * 1990-07-26 1992-12-29 Michael Black Catheter
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5269291A (en) 1990-12-10 1993-12-14 Coraje, Inc. Miniature ultrasonic transducer for plaque ablation
US5916192A (en) * 1991-01-11 1999-06-29 Advanced Cardiovascular Systems, Inc. Ultrasonic angioplasty-atherectomy catheter and method of use
US5997497A (en) 1991-01-11 1999-12-07 Advanced Cardiovascular Systems Ultrasound catheter having integrated drug delivery system and methods of using same
DE69215722D1 (en) * 1991-03-22 1997-01-23 Katsuro Tachibana Amplifier for ultrasonic therapy of diseases as well as those containing liquid pharmaceutical compositions
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
DE69224911D1 (en) * 1991-11-04 1998-04-30 Baxter Int Ultrasonic device for ablation with channel for guidewire
JPH05262673A (en) * 1992-03-19 1993-10-12 Nippon Paint Co Ltd Contrast medium for ultrasonic diagnosis
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
US5713848A (en) * 1993-05-19 1998-02-03 Dubrul; Will R. Vibrating catheter
US5261291A (en) * 1992-08-17 1993-11-16 Schoch Paul T Ergonomic apparatus for controlling a vehicle
US5318014A (en) * 1992-09-14 1994-06-07 Coraje, Inc. Ultrasonic ablation/dissolution transducer
US5362309A (en) * 1992-09-14 1994-11-08 Coraje, Inc. Apparatus and method for enhanced intravascular phonophoresis including dissolution of intravascular blockage and concomitant inhibition of restenosis
JP2746021B2 (en) * 1992-10-20 1998-04-28 富士写真光機株式会社 Ultrasound probe
US5630837A (en) * 1993-07-01 1997-05-20 Boston Scientific Corporation Acoustic ablation
JP3294387B2 (en) * 1993-07-21 2002-06-24 立花 俊郎 Ultrasonic intensity distribution measuring method
DK0717617T3 (en) * 1993-09-09 2001-02-05 Schering Ag Microparticles containing active ingredients and gas
US5509896A (en) * 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US6176842B1 (en) * 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5628728A (en) * 1995-05-31 1997-05-13 Ekos Corporation Medicine applying tool
US5558092A (en) * 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5707608A (en) * 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5648098A (en) * 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
US5735811A (en) * 1995-11-30 1998-04-07 Pharmasonics, Inc. Apparatus and methods for ultrasonically enhanced fluid delivery
DE69733815T2 (en) * 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Probe for excavation
US5836896A (en) * 1996-08-19 1998-11-17 Angiosonics Method of inhibiting restenosis by applying ultrasonic energy
US6024718A (en) * 1996-09-04 2000-02-15 The Regents Of The University Of California Intraluminal directed ultrasound delivery device
US5817048A (en) * 1997-03-20 1998-10-06 Brown University Research Foundation Ultrasonic alternative to laser-based photodynamic therapy
US6582392B1 (en) * 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
WO1998048711A1 (en) * 1997-05-01 1998-11-05 Ekos Corporation Ultrasound catheter
US6676626B1 (en) * 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6228046B1 (en) * 1997-06-02 2001-05-08 Pharmasonics, Inc. Catheters comprising a plurality of oscillators and methods for their use
JP4441000B2 (en) * 1997-06-23 2010-03-24 俊郎 立花 Biological tissue processing apparatus
US20010053384A1 (en) * 1997-07-07 2001-12-20 James F. Greenleaf Site-directed transfection with ultrasound and cavitation nuclei
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6113558A (en) * 1997-09-29 2000-09-05 Angiosonics Inc. Pulsed mode lysis method
US6007514A (en) * 1997-09-30 1999-12-28 Nita; Henry Ultrasound system with pathfinding guidewire
US6896659B2 (en) * 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
US6508816B2 (en) * 1998-03-27 2003-01-21 John H. Shadduck Medical instrument working end creating very high pressure gradients
US6475183B1 (en) * 1998-06-03 2002-11-05 Baxter International Inc. Direct dual filling device for sealing agents
US6723063B1 (en) * 1998-06-29 2004-04-20 Ekos Corporation Sheath for use with an ultrasound element
US6210356B1 (en) * 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6296619B1 (en) * 1998-12-30 2001-10-02 Pharmasonics, Inc. Therapeutic ultrasonic catheter for delivering a uniform energy dose
US6524251B2 (en) * 1999-10-05 2003-02-25 Omnisonics Medical Technologies, Inc. Ultrasonic device for tissue ablation and sheath for use therewith
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US20040019318A1 (en) * 2001-11-07 2004-01-29 Wilson Richard R. Ultrasound assembly for use with a catheter
DE60213457D1 (en) * 2001-12-03 2006-09-07 Ekos Corp Ultrasound catheter for small vessels
US20040068189A1 (en) * 2002-02-28 2004-04-08 Wilson Richard R. Ultrasound catheter with embedded conductors
EP1647232B1 (en) * 2001-12-03 2011-08-17 Ekos Corporation Catheter with multiple ultrasound radiating members
US7207989B2 (en) * 2003-10-27 2007-04-24 Biosense Webster, Inc. Method for ablating with needle electrode
US7341569B2 (en) * 2004-01-30 2008-03-11 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
WO2006110773A3 (en) * 2005-04-12 2007-07-26 Ekos Corp Ultrasound catheter with cavitation promoting surface
US20070083120A1 (en) * 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2961382A (en) * 1957-07-25 1960-11-22 Ortho Pharma Corp Urokinase-a plasmiogen activator and methods of obtaining the same
JPS52115591A (en) * 1976-02-09 1977-09-28 Fahim Mostafa S Method of local medication
GB1577551A (en) * 1976-02-09 1980-10-22 Fahim M Medication for topical application by ultrasound
WO1980002365A1 (en) * 1979-05-04 1980-11-13 Rasor Ass Inc Ultrasonic image enhancement
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4466442A (en) * 1981-10-16 1984-08-21 Schering Aktiengesellschaft Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4900540A (en) * 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4774958A (en) * 1985-12-05 1988-10-04 Feinstein Steven B Ultrasonic imaging agent and method of preparation
EP0224934A2 (en) * 1985-12-05 1987-06-10 Steven B. Feinstein Contrast agent, process for its preparation and its use for ultrasonic imaging
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
EP0278074A2 (en) * 1986-11-26 1988-08-17 Shunro Tachibana Apparatus for the endermic application of medicines
US5040537A (en) * 1987-11-24 1991-08-20 Hitachi, Ltd. Method and apparatus for the measurement and medical treatment using an ultrasonic wave
WO1989005160A1 (en) * 1987-12-02 1989-06-15 Schering Aktiengesellschaft Berlin Und Bergkamen Use of media containing bubbles in shock wave and ultrasonic therapy
WO1989005159A1 (en) * 1987-12-02 1989-06-15 Schering Aktiengesellschaft Berlin Und Bergkamen Ultrasonic or shock wave operating process and agent for implementing said process
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
EP0327490A1 (en) * 1988-02-05 1989-08-09 Schering Aktiengesellschaft Ultrasonic imaging agents, process for their preparation and their diagnostic and therapeutical use
WO1990001971A1 (en) * 1988-08-18 1990-03-08 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
JPH02180275A (en) * 1988-12-29 1990-07-13 Toshiro Tachibana Medicine injection tool having ultrasonic wave oscillation element
US4936281A (en) * 1989-04-13 1990-06-26 Everest Medical Corporation Ultrasonically enhanced RF ablation catheter
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5069664A (en) * 1990-01-25 1991-12-03 Inter Therapy, Inc. Intravascular ultrasonic angioplasty probe
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles

Non-Patent Citations (40)

* Cited by examiner, † Cited by third party
Title
B.D. Butler, J. clin. Ultrasound 14(5): 408 12 (Jun. 1986). *
B.D. Butler, J. clin. Ultrasound 14(5): 408-12 (Jun. 1986).
Bleeker et al., J. Ultrasound, Med. 9(8): 461 71 (Aug. 1990). *
Bleeker et al., J. Ultrasound, Med. 9(8): 461-71 (Aug. 1990).
Douglas L. Miller et al; Sonoporation of Cultured Cells in the Rotation Tube Exposure System, vol. 25, No. 1, 1999. *
Evan C. Unger et al. Acoustically Active Liposheres Containing Paclitaxel, vol. 11, No. 12, 1992. *
Evan C. Unger et al.; Ultrasound Enhances Gene Expression of Liposomal Transfection. Vol. 32, No. 12, Dec. 1997. *
F. Prat et al.; In Vivo Effects of Cavitation Alone or in Combination Wity Chemotherapy in a Peritoneal Carcinomatosis in the Rat. vol. 68, pp. 13 17. *
F. Prat et al.; In Vivo Effects of Cavitation Alone or in Combination Wity Chemotherapy in a Peritoneal Carcinomatosis in the Rat. vol. 68, pp. 13-17.
Feinstein et al., J. Am. Coll. Cardiol. 3(1): 14 20 (Jan. 1984). *
Feinstein et al., J. Am. Coll. Cardiol. 3(1): 14-20 (Jan. 1984).
Holland et al., J. Acoust. Soc. Am. 88(5): 2059 2069 (Nov. 1990). *
Holland et al., J. Acoust. Soc. Am. 88(5): 2059-2069 (Nov. 1990).
Keller er al., J. Ultrasound Med. 5(9): 493 8 (Sept. 1986). *
Keller er al., J. Ultrasound Med. 5(9): 493-8 (Sept. 1986).
Lang et al., Circulation 75(1): 229 234 (Jan. 1987). *
Lang et al., Circulation 75(1): 229-234 (Jan. 1987).
Leong et al., Biomaterials, vol. 7: 364 371 (Sep. 1986). *
Leong et al., Biomaterials, vol. 7: 364-371 (Sep. 1986).
Meltzer et al., J. Clin. Ultrasound 8(2): 121 7 (Apr. 1980). *
Meltzer et al., J. Clin. Ultrasound 8(2): 121-7 (Apr. 1980).
R.J. Jeffers et al.; Evaluation of the Effect of Cavitation Activity on Drug Ultrasound Synergisms, 1993. *
R.J. Jeffers et al.; Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms, 1993.
Richard Price et al.; Delivery of Colloidal Particles and Red Blood Cells to Tissue Through Microvessel Ruptures Created By Targeted Microbubble Destruction With Ultrasound, Sep. 29, 1998. *
Russell Jeffers et al.; Bimethylformamide as an Enhancer of Cavitation Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995. *
Russell Jeffers et al.; Bimethylformamide as an Enhancer of Cavitation-Induced Cell Lysis In Vitro, vol. 97, No. 1, Jan. 1995.
Shiping Bao et al.; Transfection of a Reporter plasmid into Cultured Cells By Sonoporation In Vitro. vol. 23, Nov. 6, 1997. *
T.T. Kirn, Medical news & Perspectives, JAMA 261(11): 1542 (Mar. 17, 1989). *
Tachibana K.; Tachibana S.; Albumin Microbubble Echo Contrast Materials as an Enhancer For Ultrasound Accelerated Thrombolysis, Sep. 1, 1995. *
Tachibana K.; Tachibana S.; Albumin Microbubble Echo-Contrast Materials as an Enhancer For Ultrasound Accelerated Thrombolysis, Sep. 1, 1995.
Thomas R. Porter et al.; Thrombolytic Enhancement With Perfluorocarbon Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996. *
Thomas R. Porter et al.; Thrombolytic Enhancement With Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996.
Vanderberg et al., Am. Heart J., 11574, 733 9 (Apr. 1988). *
Vanderberg et al., Am. Heart J., 11574, 733-9 (Apr. 1988).
Wheatley et al., Biomaterials 11(19): 713 7 (Nov. 1990). *
Wheatley et al., Biomaterials 11(19): 713-7 (Nov. 1990).
William J. Greenleaf et al.; Artificial Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. vol. 24, No. 4 pp. 587 595, 1998. *
William J. Greenleaf et al.; Artificial Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. vol. 24, No. 4 pp. 587-595, 1998.
Yunqiu Wu et al.; Binding as Lysing of Blood Clots Using MRX 408, May 1998. *
Yunqiu Wu et al.; Binding as Lysing of Blood Clots Using MRX-408, May 1998.

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274097A1 (en) * 1991-03-22 2008-11-06 Katsuro Tachibana Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
US7267778B2 (en) 1996-07-04 2007-09-11 Ashland Licensing And Intellectual Property Llc Device and process for treating a liquid medium
US20070158273A1 (en) * 1996-07-04 2007-07-12 Eric Cordemans De Meulenaer Device and process for treating a liquid medium
US7718073B2 (en) 1996-07-04 2010-05-18 Ashland Licensing And Intellectual Property Llc Device and process for treating a liquid medium
US8097170B2 (en) 1996-07-04 2012-01-17 Ashland Licensing And Intellectual Property Llc Process for treating a liquid medium
US6514221B2 (en) * 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
US6761729B2 (en) 2000-12-22 2004-07-13 Advanced Medicalapplications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US6533803B2 (en) 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US6569099B1 (en) 2001-01-12 2003-05-27 Eilaz Babaev Ultrasonic method and device for wound treatment
US7914470B2 (en) 2001-01-12 2011-03-29 Celleration, Inc. Ultrasonic method and device for wound treatment
US8235919B2 (en) 2001-01-12 2012-08-07 Celleration, Inc. Ultrasonic method and device for wound treatment
WO2002066060A2 (en) * 2001-02-19 2002-08-29 Dornier Medtech Systems Gmbh Method and device for ultrasound-assisted transmembrane medicament application in vitro
WO2002066060A3 (en) * 2001-02-19 2003-02-06 Dornier Medtech Systems Gmbh Method and device for ultrasound-assisted transmembrane medicament application in vitro
US6623444B2 (en) 2001-03-21 2003-09-23 Advanced Medical Applications, Inc. Ultrasonic catheter drug delivery method and device
US6478754B1 (en) * 2001-04-23 2002-11-12 Advanced Medical Applications, Inc. Ultrasonic method and device for wound treatment
US6663554B2 (en) 2001-04-23 2003-12-16 Advanced Medical Applications, Inc. Ultrasonic method and device for wound treatment
US7211248B2 (en) 2001-07-10 2007-05-01 Sonogene, L.L.C. Enhancement of transfection of DNA into the liver
US20040248832A1 (en) * 2001-07-10 2004-12-09 Michael Davidson Enhancement of transfection of dna into the liver
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
US20040002677A1 (en) * 2001-12-11 2004-01-01 Gentsler Curtis C. Alternate site gene therapy
WO2003051208A1 (en) 2001-12-14 2003-06-26 Ekos Corporation Blood flow reestablishment determination
US20080056937A1 (en) * 2002-11-04 2008-03-06 Ashland Licensing And Intellectual Property Llc Device and Process for Treating a Liquid Medium Using Ultrasound
US7632413B2 (en) 2002-11-04 2009-12-15 Ashland Licensing And Intellectual Property Llc Process for treating a liquid medium using ultrasound
US20060144801A1 (en) * 2003-07-08 2006-07-06 Mario Swinnen Device and process for treating cutting fluids using ultrasound
US7404906B2 (en) 2003-07-08 2008-07-29 Ashland Licensing & Intellectual Property Llc Device and process for treating cutting fluids using ultrasound
US20070000844A1 (en) * 2003-07-08 2007-01-04 Mario Swinnen Devices and processes for use in ultrasound treatment
US7514009B2 (en) 2003-07-08 2009-04-07 Ashland Licensing And Intellectual Property Llc Devices and processes for use in ultrasound treatment
US20060058708A1 (en) * 2003-12-24 2006-03-16 Gill Heart Method and apparatus for ultrasonically increasing the transportation of therapeutic substances through tissue
US20100081934A1 (en) * 2004-01-30 2010-04-01 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
US9102553B2 (en) 2004-06-23 2015-08-11 Solenis Technologies, L.P. Devices and methods for treating fluids utilized in electrocoating processes with ultrasound
US7448859B2 (en) 2004-11-17 2008-11-11 Ashland Licensing And Intellectual Property Llc Devices and method for treating cooling fluids utilized in tire manufacturing
US9414852B2 (en) 2004-12-09 2016-08-16 Twelve, Inc. Aortic valve repair
US20060229659A1 (en) * 2004-12-09 2006-10-12 The Foundry, Inc. Aortic valve repair
US7803168B2 (en) 2004-12-09 2010-09-28 The Foundry, Llc Aortic valve repair
WO2006063199A2 (en) 2004-12-09 2006-06-15 The Foundry, Inc. Aortic valve repair
US7713218B2 (en) 2005-06-23 2010-05-11 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US7785277B2 (en) 2005-06-23 2010-08-31 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US20100222715A1 (en) * 2005-06-24 2010-09-02 Henry Nita Methods and apparatus for intracranial ultrasound delivery
US8366620B2 (en) 2005-06-24 2013-02-05 Henry Nita Methods and apparatus for intracranial ultrasound delivery
US20110160621A1 (en) * 2005-06-24 2011-06-30 Henry Nita Methods and apparatus for dissolving intracranial blood clots
US7717853B2 (en) 2005-06-24 2010-05-18 Henry Nita Methods and apparatus for intracranial ultrasound delivery
US20070016041A1 (en) * 2005-06-24 2007-01-18 Henry Nita Methods and apparatus for intracranial ultrasound delivery
US20070055181A1 (en) * 2005-09-07 2007-03-08 Deem Mark E Apparatus for treating subcutaneous tissues
US20070055179A1 (en) * 2005-09-07 2007-03-08 Deem Mark E Method for treating subcutaneous tissues
US7601128B2 (en) 2005-09-07 2009-10-13 Cabochon Aesthetics, Inc. Apparatus for treating subcutaneous tissues
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US7588547B2 (en) 2005-09-07 2009-09-15 Cabochon Aesthetics, Inc. Methods and system for treating subcutaneous tissues
US8366643B2 (en) 2005-09-07 2013-02-05 Cabochon Aesthetics, Inc. System and method for treating subcutaneous tissues
US9005229B2 (en) 2005-09-07 2015-04-14 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9179928B2 (en) 2005-09-07 2015-11-10 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9364246B2 (en) 2005-09-07 2016-06-14 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US9248317B2 (en) 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9272124B2 (en) 2005-12-02 2016-03-01 Ulthera, Inc. Systems and devices for selective cell lysis and methods of using same
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080248554A1 (en) * 2005-12-02 2008-10-09 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20070183976A1 (en) * 2006-01-06 2007-08-09 Imarx Therapeutics, Inc. Composition for ultrasound therapy and pharmaceutical liquid composition containing the same
US20070265560A1 (en) * 2006-04-24 2007-11-15 Ekos Corporation Ultrasound Therapy System
US8562547B2 (en) 2006-06-07 2013-10-22 Eliaz Babaev Method for debriding wounds
US20080004649A1 (en) * 2006-06-07 2008-01-03 Bacoustics Llc Apparatus and methods for debridement with ultrasound energy
US7785278B2 (en) 2006-06-07 2010-08-31 Bacoustics, Llc Apparatus and methods for debridement with ultrasound energy
US7878991B2 (en) 2006-08-25 2011-02-01 Bacoustics, Llc Portable ultrasound device for the treatment of wounds
US20080089912A1 (en) * 2006-10-11 2008-04-17 Dimauro Thomas Intrathecal Injection of Microbubbles Containing a Thrombolytic Agent
US8491521B2 (en) 2007-01-04 2013-07-23 Celleration, Inc. Removable multi-channel applicator nozzle
US9039722B2 (en) 2007-10-09 2015-05-26 Ulthera, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US8900261B2 (en) 2009-08-07 2014-12-02 Ulthera, Inc. Tissue treatment system for reducing the appearance of cellulite
US9044259B2 (en) 2009-08-07 2015-06-02 Ulthera, Inc. Methods for dissection of subcutaneous tissue
US9078688B2 (en) 2009-08-07 2015-07-14 Ulthera, Inc. Handpiece for use in tissue dissection
US9757145B2 (en) 2009-08-07 2017-09-12 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9510849B2 (en) 2009-08-07 2016-12-06 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US8979881B2 (en) 2009-08-07 2015-03-17 Ulthera, Inc. Methods and handpiece for use in tissue dissection
US8900262B2 (en) 2009-08-07 2014-12-02 Ulthera, Inc. Device for dissection of subcutaneous tissue
US8920452B2 (en) 2009-08-07 2014-12-30 Ulthera, Inc. Methods of tissue release to reduce the appearance of cellulite
US8906054B2 (en) 2009-08-07 2014-12-09 Ulthera, Inc. Apparatus for reducing the appearance of cellulite
US8894678B2 (en) 2009-08-07 2014-11-25 Ulthera, Inc. Cellulite treatment methods
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US9375223B2 (en) 2009-10-06 2016-06-28 Cardioprolific Inc. Methods and devices for endovascular therapy
US9192566B2 (en) 2010-02-17 2015-11-24 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
US8740835B2 (en) 2010-02-17 2014-06-03 Ekos Corporation Treatment of vascular occlusions using ultrasonic energy and microbubbles
US9421098B2 (en) 2010-12-23 2016-08-23 Twelve, Inc. System for mitral valve repair and replacement
US9770331B2 (en) 2010-12-23 2017-09-26 Twelve, Inc. System for mitral valve repair and replacement
US9579196B2 (en) 2011-06-21 2017-02-28 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US9585751B2 (en) 2011-06-21 2017-03-07 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US9572662B2 (en) 2011-06-21 2017-02-21 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US9763780B2 (en) 2011-10-19 2017-09-19 Twelve, Inc. Devices, systems and methods for heart valve replacement
US9295552B2 (en) 2011-10-19 2016-03-29 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
EP2727544A1 (en) 2012-11-05 2014-05-07 Ekos Corporation Catheter systems and methods
US9393328B2 (en) 2013-03-14 2016-07-19 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor

Also Published As

Publication number Publication date Type
US5315998A (en) 1994-05-31 grant
EP0504881B2 (en) 2000-11-08 grant
DE69215722D1 (en) 1997-01-23 grant
CA2063529A1 (en) 1992-09-23 application
US20080274097A1 (en) 2008-11-06 application
EP0504881B1 (en) 1996-12-11 grant
DE69215722T3 (en) 2001-03-08 grant
US6585678B1 (en) 2003-07-01 grant
EP0732106A2 (en) 1996-09-18 application
EP0504881A3 (en) 1993-04-14 application
EP0504881A2 (en) 1992-09-23 application
US20030191446A1 (en) 2003-10-09 application
EP0732106A3 (en) 2003-04-09 application
DE69215722T2 (en) 1997-05-07 grant

Similar Documents

Publication Publication Date Title
Reed et al. The effect of photodynamic therapy on the microcirculation
Schroeder et al. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes
US5505700A (en) Electro-osmotic infusion catheter
US7083572B2 (en) Therapeutic delivery systems
US6443898B1 (en) Therapeutic delivery systems
US5286254A (en) Drug delivery apparatus and method
US5947921A (en) Chemical and physical enhancers and ultrasound for transdermal drug delivery
Pollay et al. Effect of mannitol and furosemide on blood-brain osmotic gradient and intracranial pressure
US7078015B2 (en) Ultrasound imaging and treatment
US5123414A (en) Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5019034A (en) Control of transport of molecules across tissue using electroporation
Alyautdin et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80–coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study
US5230882A (en) Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6749834B2 (en) Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies
US6096000A (en) Apparatus for transport of fluids across, into or from biological tissues
Lindhe et al. Changes in vascular proliferation after local application of sex hormones
US20030136402A1 (en) Method for altering the body temperature of a patient using a nebulized mist
US5490840A (en) Targeted thermal release of drug-polymer conjugates
US5236413A (en) Method and apparatus for inducing the permeation of medication into internal tissue
US6375931B2 (en) Contrast agents
US5499971A (en) Method for iontophoretically delivering drug adjacent to a heart
Raisinghani et al. Physical principles of microbubble ultrasound contrast agents
US20020102216A1 (en) Enhanced ultrasound detection with temperature-dependent contrast agents
Kuznetsov et al. Application of magnetic liposomes for magnetically guided transport of muscle relaxants and anti-cancer photodynamic drugs
US20010051131A1 (en) Methods for delivering bioactive agents

Legal Events

Date Code Title Description
AS Assignment

Owner name: EKOS CORPORATION, WASHINGTON

Free format text: MERGER;ASSIGNOR:EKOS CORPORATION;REEL/FRAME:012495/0109

Effective date: 20011119

FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

AS Assignment

Owner name: EKOS L.L.C., WASHINGTON

Free format text: LICENSE AGREEMENT;ASSIGNORS:TACHIBANA, SHUNRO;TACHIBANA, KATSURO;REEL/FRAME:014892/0626

Effective date: 19960122

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 12